2. UroToday Home
  3. Video Lectures

ESMO 2024 Videos

Futibatinib and Pembrolizumab in FGFR-Altered Urothelial Cancer - Vadim Koshkin
Outcomes with Novel Combinations in Non-Clear Cell RCC: ORACLE Study - Deepak Kilari
Nectin-4 Expression Not Predictive of Response in Enfortumab Vedotin Therapy - Thomas Powles
Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg
Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl
5-Year Survival Outcomes in Cisplatin-Ineligible Patients from EV-103 - Jonathan Rosenberg
NIAGARA Trial Shows Durvalumab Plus Chemotherapy Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles
Epigenetic Profiling Identifies Biomarkers Predicting Resistance to AR-Targeted Therapy in mCRPC - Wilbert Zwart
CheckMate 67T: Subcutaneous Nivolumab Non-Inferior to Intravenous in Advanced RCC - Laurence Albiges
Belzutifan vs Everolimus Trial Data in Advanced RCC Care - Brian Rini
ARROW Study Reveals Iodine-131 PSMA Efficacy in Advanced Cancer - Evan Yu
Metformin Study Reveals Weight Management Benefits for ADT Therapy - Silke Gillessen
LEGEND Trial Investigates EG-70 in Bladder Cancer Patients - Gautier Marcq
STAMPEDE2 Trial Explores Combination Niraparib and Abiraterone in mHSPC - Sarah Howlett & Mahaz Kayani
EV-302 Trial Analysis Evaluating Nectin-4 in Urothelial Cancer - Thomas Powles
NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles
Masofaniten in Prostate Cancer Phase 1/2 Trial: Data and Future Directions - Christos Kyriakopoulos
JCOG1019 Trial Examines Watchful Waiting vs BCG for High-Grade T1 Bladder Cancer - Hiroshi Kitamura
Oligometastatic vs Oligoprogressive RCC Treatment Strategies - Chad Tang
Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad
INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra
Variant Histology Bladder Cancer Challenges and Future Directions - Syed Hussain
Highlights in Non-Prostate GU Oncology from ESMO 2024 - Ignacio Duran
STEAP1-Targeted T-Cell Engager Demonstrates Efficacy in mCRPC Patients - William Kevin Kelly
Emerging DLL3-Targeted Therapies Demonstrate Efficacy in Neuroendocrine Prostate Cancer - Himisha Beltran
Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck
Enfortumab Vedotin and Stereotactic Radiation Tested Before Surgery in Muscle-Invasive Bladder Cancer in STAR-EV Trial - Tian Zhang
Event-Free Survival as Surrogate Endpoint in Muscle Invasive Bladder Cancer Research - Cora Sternberg
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard
First-in-Class AR Degrader Shows Promise in Castration-Resistant Prostate Cancer - Dana Rathkopf
TALAPRO-2 Analysis: Talazoparib Enzalutamide Combo in Pretreated mCRPC - Neeraj Agarwal
CONTACT-02 Trial Results: Cabozantinib Plus Atezolizumab for mCRPC - Neeraj Agarwal
PEACE-3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad
Accelerated 177Lu-PSMA-617 Protocol Tested in STAMPEDE2 - Minal Padden-Modi & Nicholas James
SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden
PATCH Trial Evaluates Transdermal Estradiol in Non-Metastatic Prostate Cancer - Duncan Gilbert
RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca
Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad
PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC - Bertrand Tombal
STAMPEDE2 SABR Trial for Oligometastatic Prostate Cancer Treatment - Hoda Abdel-Aty
UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad
Glycoproteomics in Kidney Cancer: CheckMate 9ER Biomarker Analysis - David Braun
T-Cell Engagers in Prostate Cancer Treatment - Neeraj Agarwal
Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials - Maria De Santis
Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros
CaboPoint Trial: Cabozantinib in Second-Line RCC Treatment - Laurence Albiges
EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore
ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo
ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment - Fred Saad
PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel
SunRISe-4 Trial Explores TAR-200 and Cetrelimab Combination for Bladder Cancer Treatment - Andrea Necchi
Fecal Microbiota Transplant Boosts Immunotherapy in Metastatic Renal Cell Carcinoma in TACITO-II Trial - Chiara Ciccarese
Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky
PRINCE Trial Highlights Early Detection of Prostate Cancer Progression with PSMA PET-CT - Michael Hofman
COTRIMS Trial Shows High Cure Rates with RPLND in Stage IIA/B Seminoma - Axel Heidenreich
AMBASSADOR Trial: Extended Follow-up on Adjuvant Pembrolizumab in Bladder Cancer - Andrea Apolo
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment - Oliver Sartor
Genetic Profiles in Early vs. Late Stage Urothelial Cancer - Dag Stormoen
HIF-2 Alpha Inhibitor NKT2152 Shows Impact in Renal Cell Carcinoma - Eric Jonasch
TiNivo-2 Trial Results in Advanced Renal Cell Carcinoma Treatment - Toni Choueiri